Scipher Medicine

[Available On-Demand]
Billions of dollars are wasted every year on prescription drugs that don’t work and big pharma and PBMs want to keep this broken system in place. In the treatment of RA, blockbuster TNFi therapies fail to provide adequate relief for more than half of patients. Scipher Medicine is uniquely able to aggregate massive amounts of patient genomic data to accurately identify discrete disease populations, including those unlikely to respond to TNFi therapy. Backed by leading private equity and payer organizations, Scipher has begun injecting sanity into the drug selection process and is helping to heal our healthcare system.
Company Type:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
PrismRA
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Scipher Medicine